STOCK TITAN

Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
AI

Avant Technologies (OTCQB: AVAI) and partner Ainnova Tech have secured exclusive licensing for 4 AI-driven disease detection algorithms from a major Asian healthcare institution. The algorithms, validated across 2+ million patients, target early detection of cardiovascular risk, prediabetes/Type 2 diabetes, fatty liver disease, and chronic kidney disease.

These solutions will integrate with Ainnova's VisionAI platform and existing retinal disease detection tools. The partnership plans to launch in Latin American markets and aims for FDA clearance in 2025 for U.S. market entry. The algorithms show impressive performance metrics, including 90%+ precision in coronary artery disease risk prediction and 88%+ accuracy in liver fibrosis screening.

Avant Technologies (OTCQB: AVAI) e il partner Ainnova Tech hanno ottenuto la licenza esclusiva per 4 algoritmi di rilevamento delle malattie basati su IA da una importante istituzione sanitaria asiatica. Gli algoritmi, convalidati su oltre 2 milioni di pazienti, mirano alla rilevazione precoce del rischio cardiovascolare, del prediabete/diabete di tipo 2, della steatosi epatica e della malattia renale cronica.

Queste soluzioni si integreranno con la piattaforma VisionAI di Ainnova e con gli strumenti esistenti per la rilevazione delle malattie retiniche. La partnership prevede il lancio nei mercati dell'America Latina e punta all'approvazione della FDA nel 2025 per l'ingresso nel mercato statunitense. Gli algoritmi mostrano metriche di prestazione impressionanti, tra cui oltre il 90% di precisione nella previsione del rischio di malattia coronarica e oltre l'88% di accuratezza nello screening della fibrosi epatica.

Avant Technologies (OTCQB: AVAI) y el socio Ainnova Tech han asegurado licencias exclusivas para 4 algoritmos de detección de enfermedades impulsados por IA de una importante institución de salud en Asia. Los algoritmos, validados en más de 2 millones de pacientes, se enfocan en la detección temprana del riesgo cardiovascular, prediabetes/diabetes tipo 2, enfermedad del hígado graso y enfermedad renal crónica.

Estas soluciones se integrarán con la plataforma VisionAI de Ainnova y las herramientas actuales de detección de enfermedades retinianas. La asociación planea lanzarse en los mercados de América Latina y busca la aprobación de la FDA en 2025 para ingresar al mercado estadounidense. Los algoritmos muestran métricas de rendimiento impresionantes, que incluyen más del 90% de precisión en la predicción del riesgo de enfermedad coronaria y más del 88% de precisión en el escrutinio de fibrosis hepática.

Avant Technologies (OTCQB: AVAI)와 파트너 Ainnova Tech가 아시아의 주요 의료 기관에서 AI 기반 질병 감지 알고리즘 4개에 대한 독점 라이센스를 확보했습니다. 이 알고리즘들은 200만 명 이상의 환자를 대상으로 검증되었으며, 심혈관 위험, 당뇨 전단계/2형 당뇨병, 지방간 질환 및 만성 신장 질환의 조기 감지를 목표로 합니다.

이 솔루션은 Ainnova의 VisionAI 플랫폼과 기존 망막 질병 감지 도구와 통합될 것입니다. 파트너십은 라틴 아메리카 시장에 진출할 계획이며, 2025년 미국 시장 진입을 위한 FDA 승인도 목표로 하고 있습니다. 이 알고리즘들은 관상 동맥 질환 위험 예측에서 90% 이상의 정확도와 간 섬유증 선별에서 88% 이상의 정확도를 보여주는 인상적인 성능 지표를 갖추고 있습니다.

Avant Technologies (OTCQB: AVAI) et son partenaire Ainnova Tech ont obtenu des licences exclusives pour 4 algorithmes de détection de maladies basés sur l'IA d'une grande institution de santé asiatique. Les algorithmes, validés chez plus de 2 millions de patients, visent la détection précoce du risque cardiovasculaire, du prédiabète/diabète de type 2, de la maladie du foie gras et de la maladie rénale chronique.

Ces solutions s'intégreront à la plateforme VisionAI d'Ainnova et aux outils existants de détection des maladies rétiniennes. Le partenariat prévoit un lancement sur les marchés d'Amérique latine et vise une approbation de la FDA en 2025 pour entrer sur le marché américain. Les algorithmes affichent des métriques de performance impressionnantes, avec plus de 90 % de précision dans la prédiction du risque de maladie coronarienne et plus de 88 % de précision dans le dépistage de la fibrose hépatique.

Avant Technologies (OTCQB: AVAI) und Partner Ainnova Tech haben exklusive Lizenzen für 4 KI-gesteuerte Krankheitsdiagnosealgorithmen von einer großen asiatischen Gesundheitsinstitution gesichert. Die Algorithmen, die an über 2 Millionen Patienten validiert wurden, zielen auf die frühzeitige Erkennung von kardiovaskulärem Risiko, Prädiabetes/Typ-2-Diabetes, Fettlebererkrankung und chronischen Nierenerkrankungen ab.

Diese Lösungen werden mit der VisionAI-Plattform von Ainnova und den bestehenden Werkzeugen zur Erkennung von Netzhauterkrankungen integriert. Die Partnerschaft plant den Einstieg in den lateinamerikanischen Markt und strebt 2025 die Zulassung der FDA für den Eintritt in den US-Markt an. Die Algorithmen zeigen beeindruckende Leistungsmetriken, einschließlich über 90 % Präzision bei der Vorhersage von koronaren Herzkrankheiten und über 88 % Genauigkeit beim Screening von Leberfibrose.

Positive
  • Exclusive license acquisition for 4 advanced AI algorithms
  • Algorithms validated across 2+ million patient dataset
  • High accuracy rates: 90%+ for cardiovascular risk, 88%+ for liver fibrosis
  • Planned FDA clearance pathway for 2025
  • Geographic expansion into Latin American markets
Negative
  • FDA approval not yet secured
  • Revenue generation timeline uncertain pending regulatory approvals

LAS VEGAS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner, Ainnova Tech, Inc. (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced Ainnova’s acquisition of an exclusive license for 4 groundbreaking, AI-driven algorithms from one of Asia’s most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socioeconomic populations with data from over 2 million patients, will join Ainnova’s existing diabetic retinopathy and retinal disease detection solutions. 

The 4 algorithms include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease. Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI.  

The acquisition of an exclusive license to use 4 advanced algorithms in the Americas offers Ainnova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improving patient care in the United States.

Ainnova will introduce these cutting-edge solutions in Latin America with strategic partners in primary healthcare services across key markets like Mexico and Brazil. AAC expects to build on Ainnova’s regional expansion by securing clearance from the U.S. Food and Drug Administration in 2025 to then introduce these solutions in the U.S. market.

While explaining that these efforts aim to transform the current approach to preventive care by providing accessible, efficient, and impactful health screening solutions, Ainnova’s Chief Executive Officer, Vinicio Vargas, said, “This license represents a pivotal moment for Ainnova and for its partnership with Avant as it allows us to bring world class, validated solutions to the Americas. This effort not only complements our current solutions, but it also aligns with our ongoing R&D initiatives to continue incorporating new diseases that can be detected quickly and affordably, pushing the boundaries of preventive care, and making healthcare more inclusive and accessible to all.”

The licensed algorithms enhance the company’s capabilities to empower healthcare providers with comprehensive, fast, and accessible tools for early disease detection. Using simple patient datapoints - such as demographics, lifestyle attributes, and routine measures, like blood pressure - these algorithms enable rapid risk screening, facilitating timely specialist referrals and improving health outcomes.

Key Features and Benefits of the New Algorithms:

1.   Cardiovascular Risk Assessment:

-  Accurately predicts coronary artery disease risk with over 90% precision.

-  Offers personalized recommendations through a Clinical Decision Support System (CDSS), enabling targeted preventive measures.

 2.   Prediabetes and Type 2 Diabetes Prediction:

-  Predicts the three-year risk of diabetes with an AUC of 0.861, using demographic and lifestyle data.

-  Provides tailored care plans and actionable insights to prevent disease progression.

 3.   Liver Fibrosis Screening:

-  Identifies patients at risk of advanced liver fibrosis with accuracy exceeding 88%.

-  Supports timely referral and management of non-alcoholic fatty liver disease.

4.   Chronic Kidney Disease (CKD) Monitoring:

-  Predicts CKD progression and supports preventive interventions to slow disease advancement.

-  Guides care through integrated analysis of clinical and laboratory data.

Mr. Vargas added, “This robust AI platform marks a significant step toward global adoption, ensuring that advanced AI tools are accessible to healthcare systems everywhere.”

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

 More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai  

https://www.facebook.com/AvantTechAI https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies, Inc.

info@avanttechnologies.com


FAQ

What are the 4 new AI algorithms acquired by AVAI and Ainnova?

The 4 algorithms are for early detection of: 1) cardiovascular risk, 2) prediabetes and Type 2 diabetes, 3) fatty liver disease, and 4) chronic kidney disease.

What is the accuracy rate of AVAI's new cardiovascular risk assessment algorithm?

The cardiovascular risk assessment algorithm predicts coronary artery disease risk with over 90% precision.

When does AVAI expect to receive FDA clearance for its AI algorithms?

AVAI expects to secure FDA clearance in 2025 to introduce these solutions in the U.S. market.

How many patients were used to validate AVAI's new AI algorithms?

The algorithms were validated across diverse populations with data from over 2 million patients.

Which markets will AVAI target first with its new AI algorithms?

AVAI will first introduce these solutions in Latin American markets, particularly Mexico and Brazil, before entering the U.S. market after FDA clearance.

AVANT TECHNOLOGIES INC

OTC:AVAI

AVAI Rankings

AVAI Latest News

AVAI Stock Data

84.93M
82.48M
37.46%
Software - Application
Technology
Link
United States of America
Las Vegas